LAKE BLUFF, Ill., Feb. 6 /PRNewswire/ -- Based on its pre-clinical data, Coremed, Inc., announced that its "needle-less" Alveair(TM) insulin pulmonary technology achieved better insulin bioavailability than intravenous injection of analog insulin. The technology uses a hand-held device that delivers inhaled insulin with the same units as conventionally injected insulin.
Frank K. Leung, M.D., F.A.C.E., a Harvard-trained endocrinologist and researcher, and director of Coremed, Inc.'s laboratory, termed the results an "historic milestone."
Multiple experiments were performed, Leung said that compared Alveair(TM) to intravenous and subcutaneous injections in two different animal models. Noting that the results were significant, Leung said, intravenous injection achieved quicker onset of action.
Alveair(TM) has delayed insulin peak and better AUC (area under the curve) compared to the former, he said. Recently, Coremed announced that its first human trial yielded positive results with significant efficacy using low sub-unit dosage without any obvious adverse effect and respiratory irritation.
Alveair(TM) is substantially different from other current leading inhaled insulin technology. It can minimize potential adverse reactions including immune responses because:
- It is completely aqueous soluble.
- It is vaporized before inhalation.
- It has been demonstrated, in pre-clinical trials, to have excellent
efficacy in the upper airway when delivered intra-nasally or
- It uses the lowest insulin concentration and dosage.
- Its insulin protein structure is closer to the naive molecules.
Not only, Leung said, does Alveair(TM) have the potential to replace insulin injection in many clinical conditions; it also can lower the side-effect profile. Verification and trials of Coremed's Alveair(TM) insulin technology are continuing, he said.
For the first time in history, Coremed, Inc., was able to demonstrate superior Alveair(TM) insulin efficacy and bioavailability, which equals and surpasses both subcutaneous and intravenous injections of analog insulin such as Aspar, based on its pre-clinical data.
Exclusively dedicated to the development of alternate insulin delivery, Coremed, Inc., has conducted some of the most intensive pre-clinical biological trials of oral and pulmonary-delivered insulin anywhere, resulting in its presenting published data at the American Diabetes Association and the Endocrine Society's annual meetings from 2000 to 2004.
Founded in 1994, the specialty research laboratory is developing transmucosal insulin, based on its proprietary technology, for treatment of diabetes mellitus. For more information, visit its web site http://www.coremedusa.com/
To the extent any statements made in this release relate to information that is not historical these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events beyond the company's control and other uncertainties are subject to various risk factors that could cause the company's actual results to differ materially from those expressed in any forward-looking statement.